A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Haematologica

Volumn 98, Issue 6, 2013, Pages 964-970

  Brown, Jennifer R ^a,b,c   Messmer, Bradley ^a,b,c   Werner, Lillian ^a,b,c   Davids, Matthew S ^a,b,c   Mikler, Evgeny ^a,b,c   Supko, Jeffrey G ^a,b,c   Fisher, David C ^a,b,c   LaCasce, Ann S ^a,b,c   Armand, Philippe ^a,b,c   Jacobsen, Eric ^a,b,c   Dalton, Virginia ^a,b,c   Tesar, Bethany ^a,b,c   Fernandes, Stacey M ^a,b,c   McDonough, Sean ^a,b,c   Ritz, Jerome ^a,b,c   Rassenti, Laura ^a,b,c   Kipps, Thomas J ^a,b,c   Neuberg, Donna ^a,b,c   Freedman, Arnold S ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALLOPURINOL; COTRIMOXAZOLE; RITUXIMAB;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPONATREMIA; INFECTION; INJECTION SITE REACTION; LUNG EMBOLISM; LYMPHOCYTOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; RETINA DETACHMENT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; TREATMENT OUTCOME;

EID: 84878448458     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086207     Document Type: Article

References (28)

1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10): 3554-61.
2. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768-73.
3. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27(24):3994-4001.
4. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011;118 (8):2085-93.
5. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12(13):1204-13.
6. Lepretre S, Aurran T, Mahe B, Cazin B, Tournihlac O, Maisonneuve H, et al. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL): Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucémies Aigües Et Autres Maladies Du Sang" (GOELAMS): CLL2007FMP (for fit medically patients). Blood. 2009;114:(Abstract 538).
7. Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, et al. An openlabel, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood. 2011;118(15):4079-85.
8. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062-8.
9. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113(8):2110-8.
10. Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30(14): 1647-55.
11. Zent CS, Wu W, Bowen DA, Hanson CA, Pettinger AM, Shanafelt TD, et al. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma. 2013;54(3): 476-82.
12. Bezares RF, Stemelin G, Diaz A, Argentieri D, Zubiaur EL, Garay G, et al. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leuk Lymphoma. 2011;52(10):1936-41.
13. Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, et al. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2012; 156(4):481-9.
14. Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, et al. Low dose alemtuzumab in patients with fludarabinerefractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(3):424-9.
15. Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma. 2007;48(12):2424-36.
16. Smolewski P, Szmigielska-Kaplon A, Cebula B, Jamroziak K, Rogalinska M, Kilianska Z, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2005;46(1):87-100.
17. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-7.
18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-56.
19. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48 (12):2412-7.
20. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory highrisk chronic lymphocytic leukemia. Leukemia. 2008;22(11):2048-53.
21. Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008;93(3):475-6.
22. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971-9.
23. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent lowgrade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001.
24. Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008;49(12):2256-62.
25. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-33.
26. Vojdeman FJ, Jurlander J, Veer MV, Itala-Remes M, Kimby E, Tjonnfjord GE, et al. Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. Leuk Lymphoma. 2013;54(4):790-3.
27. Ding W, Shanafelt T, Rabe KG, Call T, Zent CS, Kay N, et al. Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL). Blood. 2011;118:4152.
28. Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013;27(2):362-9.